Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis.

Advances in therapy

Outcomes of Body Contouring Surgery After Bariatric Surgery vs. GLP-1 Receptor Agonist-Induced Weight Loss: A Propensity Score Matched Analysis.

Aesthetic plastic surgery

Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.

Disease-a-month : DM

Glucagon-Like Peptide-1 Receptor Agonists in Patients with Heart Failure with Reduced Ejection Fraction.

ESC heart failure

Hemodynamic Changes in Response to GLP-1 Treatment in ICD and CRT Patients: Insights From HeartLogic Sensor Data.

European journal of heart failure

Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis.

Frontiers in endocrinology

A Multicentre, Prospective, Non-Interventional Single-Arm Study Investigating the Impact of Once-Daily Oral Semaglutide in a Real-World Adult Population With Type 2 Diabetes in Mexico.

Endocrinology, diabetes & metabolism

Widespread exposure to GLP-1RAs and weight loss-related discourse: Considering potential public health implications.

Canadian journal of public health = Revue canadienne de sante publique

New blog live on PeptiDex discussing the new FDA Peptide Reclassifications for 2026! It discusses the 14 peptides (BPC-157, Ipamorelin, CJC-1295, GHK-cu, MOTS-c, Selank, Semax, +++) which will be re-legalized & what exactly it entails! vvv https://t.co/k3P9TalgOf https://t.co/30qiSVu9qv

since we're on the subject, here are some issues with GLP-1 (noting the legend), aka Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), Zepbound (tirzepatide), and Trulicity (dulaglutide) https://t.co/rjvFWumuDp

🚨 $KITL BULLISH ALERT: FDA Peptide Reversal = Massive Catalyst for the OTC Pioneer! With RFK Jr. at HHS and the FDA now actively weighing the lift on restrictions for ~14 key peptides (BPC-157, TB-500, CJC-1295, GHK-Cu, and more), the gray-market peptide era is ending — and

Wait a minute! I'm sure FDA continues to see other unapproved but popular peptide drugs like BPC-157 continuing to be marketed. These can be risky & ineffective too. Are you going to go after companies violating regs on peptide drugs or cave into RFK Jr. on their compounding? https://t.co/yhJ7DX7wAH

• HHS Secretary Kennedy just announced the FDA is removing 12 key peptides from Category 2 restrictions starting with BPC-157 and others moving to full scientific review. • $HIMS is not a GLP-1 only company. The entire peptide industry stands ready to boom as regulated access https://t.co/3HzcTJWfS0 https://t.co/9UySm2FWBU

@LeRoi__Bear @TheDrMAWZ @sarasteinmd BPC-157: Synthetic stomach peptide promoting angiogenesis and repair. Strong animal data for tendon/wound/gut healing, NSAID alternative; limited human trials, unapproved. Rare sides, mostly none reported. GLP-1 agonists (semaglutide etc.): Curb cravings/appetite. Emerging

Common GLP 1 agents: •Semaglutide (Ozempic, Wegovy) •Liraglutide (Victoza, Saxenda) •Dulaglutide (Trulicity) •Exenatide (Byetta, Bydureon) •Tirzepatide (Mounjaro, Zepbound), a dual GLP-1 and GIP agonist with greater potency

@Dr_JoshCSimmons @maxmarchione Some have real evidence: Semaglutide/Tirzepatide are FDA-approved GLP-1 drugs with solid RCTs showing 15-20% weight loss, better insulin sensitivity, and CV benefits—worth it for metabolic issues, not just elites. BPC-157, TB4/TB-500, and KPV have promising animal data for